YASİN, Ayşe İremAydin, Sabin GoktasSÜMBÜL, BİLGEKORAL, LOKMANŞİMŞEK, MELİHGeredeli, CaglayanOzturk, AkinPerkin, PerihanDemirtas, DeryaErdemoglu, EnginHACIBEKİROĞLU, İLHANCakir, EmreTanrikulu, EdaCoban, EzgiOzcelik, MelikeCelik, SinemisTeker, FatihAKSOY, ASUDEFirat, Sedat T.Tekin, OmerKalkan, ZiyaTurken, OrhanOven, Bala B.Dane, FaysalBilici, AhmetIsikdogan, AbdurrahmanŞEKER, MesutTÜRK, HACI MEHMETGumus, Mahmut2022-02-082022-02-082022-01-01http://hdl.handle.net/20.500.12645/30384Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients.info:eu-repo/semantics/openAccessCOVID-19COVID-19 vaccinesCoronaVacSARS-CoV-2cancerchemotherapyimmunotherapymalignancyArticleWOS:00074718660000110.2217/fon-2021-124835081732